Trucchio sees 48-week data as key for Phase 3 progress, while William Blair questions drug's impact on fibrosis and weight ...

Biocryst is offloading part of its business for $250 million. Meanwhile, the former FDA leader took issue with a new policy ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...